Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Charcot-Marie-Tooth disease type 4C in Norway: Clinical characteristics, mutation spectrum and minimum prevalence.

Arntzen KA, Høyer H, Ørstavik K, Tallaksen C, Vedeler C, Østern R, Nebuchennykh M, Braathen GJ, Fagerheim T.

Neuromuscul Disord. 2018 Jun 15. pii: S0960-8966(18)30026-9. doi: 10.1016/j.nmd.2018.06.004. [Epub ahead of print]

PMID:
30001926
2.

Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study.

Giil LM, Aarsland D, Hellton K, Lund A, Heidecke H, Schulze-Forster K, Riemekasten G, Vik-Mo AO, Kristoffersen EK, Vedeler CA, Nordrehaug JE.

J Alzheimers Dis. 2018;64(3):761-774. doi: 10.3233/JAD-170882.

PMID:
29914018
3.

Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer.

Totland C, Kråkenes T, Mazengia K, Haugen M, Vedeler C.

Oncotarget. 2018 May 8;9(35):23975-23986. doi: 10.18632/oncotarget.25252. eCollection 2018 May 8.

4.

Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.

Panja D, Vedeler CA, Schubert M.

Neuropathol Appl Neurobiol. 2018 Apr 21. doi: 10.1111/nan.12492. [Epub ahead of print]

PMID:
29679372
5.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

6.

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.

Olberg HK, Eide GE, Cox RJ, Jul-Larsen Å, Lartey SL, Vedeler CA, Myhr KM.

Eur J Neurol. 2018 Mar;25(3):527-534. doi: 10.1111/ene.13537. Epub 2018 Jan 6.

PMID:
29205701
7.

CCDC104 Antibodies and Mitosis of Cancer Cells.

Eichler TW, Totland C, Haugen M, Vedeler CA.

Scand J Immunol. 2018 Feb;87(2):109-110. doi: 10.1111/sji.12634. No abstract available.

PMID:
29193323
8.

Reduced glucose transporter-1 in brain derived circulating endothelial cells in mild Alzheimer's disease patients.

Vogelsang P, Giil LM, Lund A, Vedeler CA, Parkar AP, Nordrehaug JE, Kristoffersen EK.

Brain Res. 2018 Jan 1;1678:304-309. doi: 10.1016/j.brainres.2017.10.035. Epub 2017 Nov 2.

PMID:
29102777
9.

Selective intrathecal enrichment of G1m1-positive B cells in multiple sclerosis.

Lossius A, Tomescu-Baciu A, Holmøy T, Vedeler CA, Røsjø E, Lorentzen ÅR, Casetta I, Vartdal F.

Ann Clin Transl Neurol. 2017 Sep 27;4(10):756-761. doi: 10.1002/acn3.451. eCollection 2017 Oct.

10.

Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.

Raspotnig M, Haugen M, Thorsteinsdottir M, Stefansson I, Salvesen HB, Storstein A, Vedeler CA.

Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471. doi: 10.1007/s00262-017-2041-8. Epub 2017 Jul 14.

PMID:
28710511
11.

Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function.

Giil LM, Vedeler CA, Kristoffersen EK, Nordrehaug JE, Heidecke H, Dechend R, Schulze-Forster K, Muller DN, von Goetze VS, Cabral-Marques O, Riemekasten G, Vogelsang P, Nygaard S, Lund A, Aarsland D.

J Alzheimers Dis. 2017;59(3):929-939. doi: 10.3233/JAD-170245.

PMID:
28697567
12.

Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories.

Bader LI, Solberg SM, Kaada SH, Bolstad N, Warren DJ, Gavasso S, Gjesdal CG, Vedeler CA.

Scand J Immunol. 2017 Sep;86(3):165-170. doi: 10.1111/sji.12572.

PMID:
28561325
13.

[Multiple sclerosis - a mitochondria-mediated disease?]

Varhaug KN, Vedeler CA, Tzoulis C, Bindoff LA.

Tidsskr Nor Laegeforen. 2017 Feb 21;137(4):284-287. doi: 10.4045/tidsskr.16.0210. eCollection 2017 Feb. Review. Norwegian.

14.

Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis.

Varhaug KN, Vedeler CA, Myhr KM, Aarseth JH, Tzoulis C, Bindoff LA.

Mitochondrion. 2017 May;34:32-35. doi: 10.1016/j.mito.2016.12.003. Epub 2016 Dec 23.

PMID:
28017684
15.

Morvan syndrome with Caspr2 antibodies. Clinical and autopsy report.

Sundal C, Vedeler C, Miletic H, Andersen O.

J Neurol Sci. 2017 Jan 15;372:453-455. doi: 10.1016/j.jns.2016.10.046. Epub 2016 Oct 28. No abstract available.

PMID:
27802867
16.

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15. doi: 10.1136/jnnp-2015-312601. Epub 2016 Apr 25.

17.

Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.

Storstein A, Raspotnig M, Vitaliani R, Giometto B, Graus F, Grisold W, Honnorat J, Vedeler CA.

J Neurol. 2016 May;263(5):1001-1007. doi: 10.1007/s00415-016-8090-7. Epub 2016 Mar 23.

PMID:
27007485
18.

A case of relapsing-remitting facial palsy and ipsilateral brachial plexopathy caused by HSV-1.

Alstadhaug KB, Kvarenes HW, Prytz J, Vedeler C.

J Clin Virol. 2016 May;78:62-5. doi: 10.1016/j.jcv.2016.03.003. Epub 2016 Mar 10.

PMID:
26991053
19.

Paraneoplastic syndrome-associated neuronal antibodies in adult ADHD.

Haukanes BI, Hegvik TA, Eichler T, Haavik J, Vedeler C.

J Neuroimmunol. 2015 Nov 15;288:87-91. doi: 10.1016/j.jneuroim.2015.08.018. Epub 2015 Sep 1.

20.

Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease.

Giil LM, Kristoffersen EK, Vedeler CA, Aarsland D, Nordrehaug JE, Winblad B, Cedazo-Minguez A, Lund A, Reksten TR.

J Alzheimers Dis. 2015;47(2):523-9. doi: 10.3233/JAD-150053.

PMID:
26401573
21.

Fingolimod does not enhance cerebellar remyelination in the cuprizone model.

Alme MN, Nystad AE, Bø L, Myhr KM, Vedeler CA, Wergeland S, Torkildsen Ø.

J Neuroimmunol. 2015 Aug 15;285:180-6. doi: 10.1016/j.jneuroim.2015.06.006. Epub 2015 Jun 19.

22.

Biomarkers Related to Carotid Intima-Media Thickness and Plaques in Long-Term Survivors of Ischemic Stroke.

Waje-Andreassen U, Naess H, Thomassen L, Maroy TH, Mazengia KY, Eide GE, Vedeler CA.

Transl Stroke Res. 2015 Aug;6(4):276-83. doi: 10.1007/s12975-015-0403-0. Epub 2015 May 8.

23.

Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.

Raspotnig M, Vedeler C, Storstein A.

J Neurol Sci. 2015 Jan 15;348(1-2):41-5. doi: 10.1016/j.jns.2014.10.040. Epub 2014 Nov 5.

PMID:
25467140
24.

Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.

Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA.

Acta Neuropathol. 2014 Dec;128(6):835-52. doi: 10.1007/s00401-014-1351-6. Epub 2014 Oct 24.

25.

Paraneoplastic Hu and CRMP5 antibodies are present in smokers without cancer or neurological disease.

Qvale TH, Storstein A, Mazengia K, Eagan TM, Bakke PS, Vedeler CA.

Respirology. 2014 Jul;19(5):730-4. doi: 10.1111/resp.12292. Epub 2014 Apr 3.

26.

Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.

Gavasso S, Mosleth EF, Marøy T, Jørgensen K, Nakkestad HL, Gjertsen BT, Myhr KM, Vedeler C.

PLoS One. 2014 Feb 19;9(2):e88632. doi: 10.1371/journal.pone.0088632. eCollection 2014.

27.

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.

Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM.

Mult Scler. 2014 Jul;20(8):1074-80. doi: 10.1177/1352458513513970. Epub 2014 Jan 16.

PMID:
24436455
28.

[Neuromyelitis optica].

Kvistad SA, Wergeland S, Torkildsen Ø, Myhr KM, Vedeler CA.

Tidsskr Nor Laegeforen. 2013 Oct 15;133(19):2057-61. doi: 10.4045/tidsskr.13.0608. Review. Norwegian.

29.

The Norwegian Stroke in the Young Study (NOR-SYS): rationale and design.

Fromm A, Thomassen L, Naess H, Meijer R, Eide GE, Kråkenes J, Vedeler CA, Gerdts E, Larsen TH, Kuiper KK, Laxdal E, Russell D, Tatlisumak T, Waje-Andreassen U.

BMC Neurol. 2013 Jul 17;13:89. doi: 10.1186/1471-2377-13-89.

30.

CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.

Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, Haukanes BI, Vedeler CA.

PLoS One. 2013 Jun 18;8(6):e66002. doi: 10.1371/journal.pone.0066002. Print 2013.

31.

Avidity of onconeural antibodies is of clinical relevance.

Totland C, Ying M, Haugen M, Mazengia K, Storstein A, Aarseth J, Martinez A, Vedeler C.

Cancer Immunol Immunother. 2013 Aug;62(8):1393-6. doi: 10.1007/s00262-013-1442-6. Epub 2013 Jun 4.

PMID:
23733227
32.

Progressive striatal necrosis associated with anti-NMDA receptor antibodies.

Tzoulis C, Vedeler C, Haugen M, Storstein A, Tran GT, Gjerde IO, Biermann M, Schwarzlmüller T, Bindoff LA.

BMC Neurol. 2013 May 31;13:55. doi: 10.1186/1471-2377-13-55.

33.

Neurological manifestations related to level of voltage-gated potassium channel antibodies.

Olberg H, Haugen M, Storstein A, Vedeler CA.

J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):941-3. doi: 10.1136/jnnp-2013-305252. Epub 2013 Apr 17. No abstract available.

PMID:
23595945
34.

Ischaemic stroke at a young age is a serious event--final results of a population-based long-term follow-up in Western Norway.

Waje-Andreassen U, Thomassen L, Jusufovic M, Power KN, Eide GE, Vedeler CA, Naess H.

Eur J Neurol. 2013 May;20(5):818-23. doi: 10.1111/ene.12073. Epub 2013 Jan 7.

PMID:
23293975
35.

Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.

Kroksveen AC, Guldbrandsen A, Vedeler C, Myhr KM, Opsahl JA, Berven FS.

Acta Neurol Scand Suppl. 2012;(195):90-6. doi: 10.1111/ane.12029.

PMID:
23278663
36.

Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.

Gavasso S, Torkildsen Ø, Marøy TH, Ulvestad E, Myhr KM, Vedeler CA.

Acta Neurol Scand Suppl. 2012;(195):84-9. doi: 10.1111/ane.12026.

PMID:
23278662
37.

Small fibre neuropathy in Fabry disease.

Bertelsen AK, Tøndel C, Krohn J, Bull N, Aarseth J, Houge G, Mellgren SI, Vedeler CA.

J Neurol. 2013 Mar;260(3):917-9. doi: 10.1007/s00415-012-6800-3. Epub 2012 Dec 21. No abstract available.

PMID:
23263477
38.

Treatment for paraneoplastic neuropathies.

Giometto B, Vitaliani R, Lindeck-Pozza E, Grisold W, Vedeler C.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD007625. doi: 10.1002/14651858.CD007625.pub2. Review.

PMID:
23235647
39.

Chronic inflammatory demyelinating polyneuropathy (CIDP).

Vedeler CA, Farbu E, Mellgren SI.

Acta Neurol Scand Suppl. 2013;(196):48-51. doi: 10.1111/ane.12049. Review.

PMID:
23190291
40.

Difficult treatment--many options.

Vedeler C.

Tidsskr Nor Laegeforen. 2012 Oct 16;132(19):2185. doi: 10.4045/tidsskr.12.0926. English, Norwegian. No abstract available.

41.

Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM.

Kroksveen AC, Aasebø E, Vethe H, Van Pesch V, Franciotta D, Teunissen CE, Ulvik RJ, Vedeler C, Myhr KM, Barsnes H, Berven FS.

J Proteomics. 2013 Jan 14;78:312-25. doi: 10.1016/j.jprot.2012.09.037. Epub 2012 Oct 8.

PMID:
23059536
42.

[Baby with respiratory problems and cardiac arrest].

Greve-Isdahl F, Holmaas G, Vedeler CA.

Tidsskr Nor Laegeforen. 2012 Feb 21;132(4):429-31. doi: 10.4045/tidsskr.10.1324. Norwegian.

43.

Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.

Gavasso S, Gjertsen B, Anderssen E, Myhr K, Vedeler C.

Mult Scler. 2012 Aug;18(8):1116-24. doi: 10.1177/1352458511434066. Epub 2012 Jan 27.

PMID:
22287540
44.

Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases/small cell lung cancer.

Trier NH, Hansen PR, Vedeler CA, Somnier FE, Houen G.

J Neuroimmunol. 2012 Feb 29;243(1-2):25-33. doi: 10.1016/j.jneuroim.2011.12.020. Epub 2012 Jan 20.

PMID:
22264992
45.

Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.

Raspotnig M, Vedeler CA, Storstein A.

Acta Neurol Scand Suppl. 2011;(191):83-8. doi: 10.1111/j.1600-0404.2011.01549.x. Review.

PMID:
21711262
46.

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R.

Mult Scler. 2011 Sep;17(9):1074-8. doi: 10.1177/1352458511404271. Epub 2011 Apr 20.

PMID:
21511692
47.

A family with atypical CADASIL.

Vedeler C, Bindoff L.

J Neurol. 2011 Oct;258(10):1888-9. doi: 10.1007/s00415-011-6023-z. Epub 2011 Apr 5. No abstract available.

48.

Onconeural antibodies: improved detection and clinical correlations.

Storstein A, Monstad SE, Haugen M, Mazengia K, Veltman D, Lohndal E, Aarseth J, Vedeler C.

J Neuroimmunol. 2011 Mar;232(1-2):166-70. doi: 10.1016/j.jneuroim.2010.10.009. Epub 2010 Nov 19.

PMID:
21093932
49.

CDR2 antigen and Yo antibodies.

Totland C, Aarskog NK, Eichler TW, Haugen M, Nøstbakken JK, Monstad SE, Salvesen HB, Mørk S, Haukanes BI, Vedeler CA.

Cancer Immunol Immunother. 2011 Feb;60(2):283-9. doi: 10.1007/s00262-010-0943-9. Epub 2010 Nov 16.

50.

Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ; European Federation of Neurological Societies.

Eur J Neurol. 2011 Jan;18(1):19-e3. doi: 10.1111/j.1468-1331.2010.03220.x. Epub 2010 Sep 29.

Supplemental Content

Loading ...
Support Center